---
schema_version: "secwatch.filing_event.v1"
accession: "0001607062-21-000187"
form_type: "8-K"
ticker: "RGBP"
cik: "0001589150"
company_name: "Regen BioPharma Inc"
filed_at: "2021-07-02T23:59:59+00:00"
generated_at: "2026-06-30T07:35:32.894259+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Regen Biopharma subsidiary KCL receives USPTO patent grant for NR2F6 inhibition cancer therapy

## Summary
- KCL Therapeutics (Regen Biopharma subsidiary) granted USPTO patent for NR2F6 inhibition method.
- Invention pertains to generating IL-17 antitumor effector cells by inhibiting NR2F6.
- NR2F6 described as an immune checkpoint and cancer stem cell differentiator.

## SEC filing metadata
- accession: 0001607062-21-000187
- form_type: 8-K
- ticker: RGBP
- cik: 0001589150
- company_name: Regen BioPharma Inc
- filed_at: 2021-07-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000187/0001607062-21-000187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1589150/000160706221000187/rgbp070221form8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001607062-21-000187
- JSON: https://secwatch.observer/filing/0001607062-21-000187.json
- Plain text: https://secwatch.observer/filing/0001607062-21-000187.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.